PLXP.Q Stock Overview
PLx Pharma Winddown Corp. operates as a commercial-stage drug delivery platform technology company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PLx Pharma Winddown Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.70 |
| 52 Week Low | US$0.000001 |
| Beta | 3.41 |
| 11 Month Change | -99.50% |
| 3 Month Change | -99.98% |
| 1 Year Change | -100.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M
Aug 12Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?
May 10
Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable
Nov 03We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow
Sep 23PLx Pharma: First Commercial Launch Makes It Attractive
Sep 17PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business
Jun 15Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?
Mar 05PLx Pharma EPS misses by $0.10
Nov 16Shareholder Returns
| PLXP.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 4.2% | 2.0% |
| 1Y | -100.0% | 13.7% | 32.4% |
Return vs Industry: PLXP.Q underperformed the US Pharmaceuticals industry which returned -4.4% over the past year.
Return vs Market: PLXP.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| PLXP.Q volatility | |
|---|---|
| PLXP.Q Average Weekly Movement | 54.0% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PLXP.Q's share price has been volatile over the past 3 months.
Volatility Over Time: PLXP.Q's weekly volatility (54%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 18 | Pat Lonergan | plxpharma.com |
PLx Pharma Winddown Corp. operates as a commercial-stage drug delivery platform technology company in the United States. The company’s lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever.
PLx Pharma Winddown Corp. Fundamentals Summary
| PLXP.Q fundamental statistics | |
|---|---|
| Market cap | US$30.00 |
| Earnings (TTM) | -US$27.58m |
| Revenue (TTM) | US$4.54m |
0.0x
P/S Ratio0.0x
P/E RatioIs PLXP.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLXP.Q income statement (TTM) | |
|---|---|
| Revenue | US$4.54m |
| Cost of Revenue | US$4.34m |
| Gross Profit | US$203.00k |
| Other Expenses | US$27.78m |
| Earnings | -US$27.58m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 4.47% |
| Net Profit Margin | -606.91% |
| Debt/Equity Ratio | 0% |
How did PLXP.Q perform over the long term?
See historical performance and comparison